biostudies-literatureUnknown139(16)Craven BThe COVID-19 pandemic has resulted in the rapid development of a range of vaccines against SARS-CoV-2. Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare but life-threatening complication of primarily adenoviral-based vaccines associated with the presence of antibodies to a PF4/polyanion neoepitope and measured by using enzyme-linked immunosorbent assays. Presented are serial anti-PF4/polyanion antibody, platelet, and D-dimer measurements in a large cohort of patients and their relation to relapse. Overall, 51% of patients using the Stago assay had persistently positive anti-PF4/polyanion levels 100 days' postdiagnosis, whereas 94% of patients monitored by using the Immucor assay remain positive. The median duration of positivity of the PF4 assay is 87 days, with 72% oBlood2553-2560https://www.ebi.ac.uk/biostudies/studies/S-EPMC8912978biostudies-literatureNatural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis.PMC8912978Lester WCraven BPavord SChudakou PSingh DMakris MScully MThomas WCalvert ABoyce SDavies CKanny AHermans JBart-Smith EArnott SHunt BJfalseNatural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis.The COVID-19 pandemic has resulted in the rapid development of a range of vaccines against SARS-CoV-2. Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare but life-threatening complication of primarily adenoviral-based vaccines associated with the presence of antibodies to a PF4/polyanion neoepitope and measured by using enzyme-linked immunosorbent assays. Presented are serial anti-PF4/polyanion antibody, platelet, and D-dimer measurements in a large cohort of patients and their relation to relapse. Overall, 51% of patients using the Stago assay had persistently positive anti-PF4/polyanion levels 100 days' postdiagnosis, whereas 94% of patients monitored by using the Immucor assay remain positive. The median duration of positivity of the PF4 assay is 87 days, with 72% o2022-01-01T00:00:00Z2022 Apr2025-04-04T08:24:22.269Z2025-04-04T08:24:22.269ZS-EPMC89129783526342010.1182/blood.2021014684